Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 Apr;52(4):850–861. doi: 10.1172/JCI107249

Partial Purification of Plasma Thromboplastin Antecedent (Factor XI) and its Activation by Trypsin

Hidehiko Saito 1, Oscar D Ratnoff 1, James S Marshall 1, Jack Pensky 1
PMCID: PMC302332  PMID: 4266422

Abstract

A persistent puzzle in our understanding of hemostasis has been the absence of hemorrhagic symptoms in the majority of patients with Hageman trait, the hereditary deficiency of Hageman factor (factor XII). One proposed hypothesis is that alternative mechanisms exist in blood through which plasma thromboplastin antecedent (PTA, factor XI) can become active in the absence of Hageman factor. In order to test this hypothesis, the effect of several proteolytic enzymes, among them thrombin, plasma kallikrein, and trypsin, was tested upon unactivated PTA. PTA was prepared from normal human plasma by Ca3(PO4)2 adsorption, ammonium sulfate fractionation, and successive chromatography on QAE-Sephadex (twice). Sephadex-G150, and SP-Sephadex. The partially purified PTA was almost all in its native form, with a specific activity of 45-70 U/mg protein; the yield was about 10%. It contained no measurable amounts of other known clotting factors, plasmin, plasminogen, nor IgG. Incubation of PTA with trypsin generated potent clot-promoting activity that corrected the abnormally long clotting time of plasma deficient in Hageman factor or PTA but not in Christmas factor. This clot-promoting agent behaved like activated PTA on gel filtration (apparent molecular weight: 185,000) and was specifically inhibited by an antiserum directed against activated PTA. These data suggested that PTA can be converted into its active form by trypsin. PTA was not activated by thrombin, chymotrypsin, papain, ficin, plasmin, plasma kallikrein, tissue thromboplastin, or C̄. Trypsin converted PTA to its active form enzymatically. Whether trypsin serves to activate PTA in vivo is not yet clear.

Full text

PDF
852

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALEXANDER B., PECHET L., KLIMAN A. Proteolysis, fibrinolysis, and coagulation. Significance in thrombolytic therapy. Circulation. 1962 Oct;26:596–611. doi: 10.1161/01.cir.26.4.596. [DOI] [PubMed] [Google Scholar]
  2. Andrews P. The gel-filtration behaviour of proteins related to their molecular weights over a wide range. Biochem J. 1965 Sep;96(3):595–606. doi: 10.1042/bj0960595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berg W., Korsan-Bengtsen K., Ygge J. Preparation of human plasminogen suitable as substrate for quantitative determination of plasminogen activators. Thromb Diath Haemorrh. 1966 May 15;15(3):511–518. [PubMed] [Google Scholar]
  4. Cochrane C. G., Wuepper K. D. The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor). J Exp Med. 1971 Oct 1;134(4):986–1004. doi: 10.1084/jem.134.4.986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cuatrecasas P. Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads. J Biol Chem. 1970 Jun;245(12):3059–3065. [PubMed] [Google Scholar]
  6. Donaldson V. H., Ratnoff O. D. Hageman factor: alterations in physical properties during activation. Science. 1965 Nov 5;150(3697):754–756. doi: 10.1126/science.150.3697.754. [DOI] [PubMed] [Google Scholar]
  7. Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med. 1970 Nov;76(5):809–815. [PubMed] [Google Scholar]
  8. Forbes C. D., Ratnoff O. D. Studies on plasma thromboplastin antecedent (factor XI), PTA deficiency and inhibition of PTA by plasma: pharmacologic inhibitors and specific antiserum. J Lab Clin Med. 1972 Jan;79(1):113–127. [PubMed] [Google Scholar]
  9. GAREN A., LEVINTHAL C. A fine-structure genetic and chemical study of the enzyme alkaline phosphatase of E. coli. I. Purification and characterization of alkaline phosphatase. Biochim Biophys Acta. 1960 Mar 11;38:470–483. doi: 10.1016/0006-3002(60)91282-8. [DOI] [PubMed] [Google Scholar]
  10. KLINE D. L., FISHMAN J. B. Proactivator function of human plasmin as shown by lysine esterase assay. J Biol Chem. 1961 Oct;236:2807–2812. [PubMed] [Google Scholar]
  11. Kaplan A. P., Austen K. F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696–712. doi: 10.1084/jem.133.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kass L., Ratnoff O. D., Leon M. A. Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A. J Clin Invest. 1969 Feb;48(2):351–358. doi: 10.1172/JCI105991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kociba G. J., Ratnoff O. D., Loeb W. F., Wall R. L., Heider L. E. Bovine plasma thromboplastin antecedent (Factor XI) deficiency. J Lab Clin Med. 1969 Jul;74(1):37–41. [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Ogston D., Bennett N. B., Ogston C. M., Ratnoff O. D. The assay of a plasma component necessary for the generation of a plasminogen activator in the presence of Hageman factor (Hageman factor co-factor). Br J Haematol. 1971 Feb;20(2):209–216. doi: 10.1111/j.1365-2141.1971.tb07029.x. [DOI] [PubMed] [Google Scholar]
  16. Ogston D., Ogston C. M., Ratnoff O. D., Forbes C. D. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest. 1969 Oct;48(10):1786–1801. doi: 10.1172/JCI106145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pitlick F. A., Nemerson Y., Gottlieb A. J., Gordon R. G., Williams W. J. Peptidase activity associated with the tissue factor of blood coagulation. Biochemistry. 1971 Jun 22;10(13):2650–2657. doi: 10.1021/bi00789a036. [DOI] [PubMed] [Google Scholar]
  18. Prentice C. R., Ratnoff O. D., Breckenridge R. T. Experiments on the nature of the prothrombin-converting principle: alteration of proaccelerin by thrombin. Br J Haematol. 1967 Nov;13(6):898–914. doi: 10.1111/j.1365-2141.1967.tb08860.x. [DOI] [PubMed] [Google Scholar]
  19. RATNOFF O. D., DAVIE E. W., MALLETT D. L. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Invest. 1961 May;40:803–819. doi: 10.1172/JCI104314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ratnoff O. D., Naff G. B. The conversion of C'IS to C'1 esterase by plasmin and trypsin. J Exp Med. 1967 Feb 1;125(2):337–358. doi: 10.1084/jem.125.2.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ratnoff O. D., Pensky J., Ogston D., Naff G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med. 1969 Feb 1;129(2):315–331. doi: 10.1084/jem.129.2.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ratnoff O. D. Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI). J Lab Clin Med. 1972 Nov;80(5):704–710. [PubMed] [Google Scholar]
  23. Ratnoff O. D. The biology and pathology of the initial stages of blood coagulation. Prog Hematol. 1966;5:204–245. [PubMed] [Google Scholar]
  24. SIEGELMAN A. M., CARLSON A. S., ROBERTSON T. Investigation of serum trypsin and related substances. I. The quantitative demonstration of trypsinlike activity in human blood serum by a micromethod. Arch Biochem Biophys. 1962 Apr;97:159–163. doi: 10.1016/0003-9861(62)90058-9. [DOI] [PubMed] [Google Scholar]
  25. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES